Drug Database
PA

paliperidone

✓ Approved

Torrent Pharmaceuticals Limited · DRD2 · Small Molecule

What is paliperidone?

paliperidone is a small molecule developed by Torrent Pharmaceuticals Limited. It is approved for therapeutic indications via oral (po).

Drug Profile

CompanyTorrent Pharmaceuticals Limited
Drug ClassSmall Molecule
Molecular TargetDRD2, HTR2A, HTR7
RouteOral (PO)
StatusApproved

Mechanism of Action

Molecular Targets

paliperidone acts on 3 molecular targets:

DRD2dopamine receptor D2 (D2DR, D2R)
HTR2A5-hydroxytryptamine receptor 2A (5-HT2A, HTR2)
HTR75-hydroxytryptamine receptor 7 (5-HT7)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

paliperidone is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Psychiatric disordersSchizophrenia✓ Approved

Related Research Articles

PubMedCase reports in neurology2026-07-25

Korsakoff Syndrome in a Late Adolescent with Wernicke Encephalopathy: A Case Report.

Bourcier Dax D, Holland Joanna J, Veysey Andrew A, Khan Naeem N et al.

Wernicke encephalopathy (WE) is a neurological emergency characterized by acute encephalopathy, oculomotor dysfunction, and ataxia, and may progress to Korsakoff syndrome - a disorder characterized by irreversible global episodic amnesia. Although classically linked to alcohol misuse, WE also arises in medical and psychiatric conditions associated with nutritional deficiency. We report an 18-year-old male with schizophrenia, non-adherent to antipsychotic treatment, who was admitted with disorganization, catatonia, and dehydration. After several days of minimal nutrition (including dextrose-containing fluids), oral lorazepam, and intramuscular olanzapine, he developed acute WE with worsening catatonia. Intravenous thiamine and continued lorazepam rapidly improved his level of consciousness. Laboratory testing revealed undetectable thiamine, and MRI findings were consistent with WE. Despite oral multivitamin supplementation, catatonia improved only after escalation to intravenous lorazepam and electroconvulsive therapy. As catatonia improved, symptomatology of schizophrenia emerged and improved significantly with paliperidone therapy. As schizophrenia symptoms improved, complete anterograde and partial retrograde amnesia, apathy, and anosognosia emerged, consistent with Korsakoff syndrome. He continued to meet diagnostic criteria at 3-year follow-up. This complex case demonstrates the importance of maintaining a suspicion of thiamine deficiency in patients with a history of nutritional depletion of greater or equal to 2 weeks. Prompt initiation and continuation of thiamine therapy while investigating and treating concurrent diagnoses can reduce the risk of WE and Korsakoff syndrome.

PubMedInternational journal of pharmaceutics2026-07-25

Droplet microfluidic fabrication of dimpled poly(lactic acid)-poloxamer microparticles for tuneable depot formulations.

Balla Evangelia E, Bikiaris Nikolaos D ND, Christodoulou Ermis P EP, Zamboulis Alexandra A et al.

The development of long-acting injectable (LAI) formulations with precise control over drug release and high batch-to-batch reproducibility remains a major challenge, primarily due to limited control over particle formation dynamics and internal microstructure. Here, we integrate droplet microfluidics with newly synthesized poly(lactic acid)-poloxamer-poly(lactic acid) (PLA_PLU_PLA) triblock copolymers (having 0.05 to 0.2 wt% PLU) to engineer drug-loaded microparticles (MPs) with controlled interfacial assembly and phase behaviour. This approach enabled the reproducible fabrication of highly monodisperse MPs (coefficient of variation for MPs' size was below 10%) with tuneable size and morphology. MPs with diameters ranging from 34.8 ± 0.9 to 44.4 ± 1.6 μm were produced, while systematic variation of PLU content enabled precise modulation of surface architecture, producing golf-ball-like dimples and reduced porosity at higher and lower PLU content, respectively. This transition suggests PLU-dependent modulation of interfacial tension and phase segregation during solvent extraction, governing surface characteristics. Enzymatic degradation studies revealed a non-linear dependence on composition, with 0.1 wt% PLU MPs exhibiting the slowest degradation (10.7 ± 1.5% weight loss at 20 days), indicating a balance between hydrophilicity-driven water uptake and reduced matrix accessibility. Using paliperidone palmitate (PP) as a model active pharmaceutical ingredient (API), MPs with intermediate PLU content showed the most prolonged release profile (∼ 42% over 14 days), with phenomenological release modelling suggesting a balance between diffusional transport and matrix erosion governed by composition-dependent characteristic. Drug loading and encapsulation efficiency (11.8-16.5% and 68.0-88.0%, respectively) were composition-dependent, reflecting altered API-copolymer partitioning. Collectively, these findings establish the use of droplet microfluidics combined with rational PLA/PLU triblock copolymer design as a powerful and versatile platform for engineering next-generation depot formulations with tuneable MPs' morphology, degradation, and drug release performance.

PubMedClinical case reports2026-07-23

Tardive Dyskinesia Induced by Long-Acting Injectable Paliperidone Palmitate Once Every 3 Months in a Patient With Schizophrenia: A Case Report and Literature Review.

Ge Jianmiao J, Li Jing J, Ma Ruiting R, Tong Lijun L et al.

Prolonged use of long-acting injectable antipsychotics may lead to tardive dyskinesia (TD). Clinicians should regularly assess the risk of TD. They should promptly discontinue the long-acting medication, switch to an antipsychotic with a low risk of TD, and initiate supportive care as soon as signs of TD appear.

PubMedDusunen adam : Bakirkoy Ruh ve Sinir Hastaliklari Hastanesi yayin organi2026-07-16

The knowledge and attitudes of psychiatrists toward antipsychotic long-acting injections in Turkiye.

Fidan Yagmur Sever YS, Calli Sumeyye Yasemin SY, Kizilsert Arda A, Gokce Cengiz C et al.

Schizophrenia is a chronic psychiatric disorder frequently complicated by nonadherence to oral antipsychotics. Long-acting injectable antipsychotics (LAIA) improve adherence and reduce relapse, yet their use differs across countries. This study examined the knowledge, attitudes, and prescribing practices of psychiatrists in Türkiye regarding LAIA treatments. A cross-sectional online survey was conducted between March 2024 and March 2025. The questionnaire, distributed to 1,255 psychiatrists, collected sociodemographic data, clinical workload, and responses to 13 attitude statements. A total of 157 psychiatrists completed the survey and met inclusion criteria. Descriptive statistics and chi-square analyses were performed to assess associations between attitudes and demographic or institutional characteristics. Participants had a mean age of 38 years; 72.6% were female. Most respondents (79.6%) reported routinely considering LAIA therapy. Paliperidone (80.3%) and aripiprazole (47.8%) were the most frequently preferred agents. Positive attitudes were more common among psychiatrists with longer professional experience and those working in institutions with inpatient clinics. More experienced clinicians were significantly less likely to endorse misconceptions, such as the belief that LAIAs limit therapeutic relationships, are costlier than hospitalization, or represent an unpleasant treatment for patients. Attitudes varied across workplace settings: private sector psychiatrists more often expressed caution, particularly regarding first-episode psychosis. Psychiatrists in Türkiye generally recognize the value of LAIAs beyond nonadherent cases, with professional experience and institutional context shaping prescribing patterns. While favorable attitudes predominate, misconceptions and systemic barriers persist. Targeted education, supportive policies, and shared decision-making strategies may promote wider, evidence-based use of LAIAs in clinical practice.

PubMedThe journal of ECT2026-07-15

Pulmonary Aspiration During Electroconvulsive Therapy in a Patient on Multiple Psychotropic Medications: A Case Report and Risk-Stratified Approach to Preprocedural Gastric Ultrasound.

Chauhan Vikas V, Muppuri Ikya I, Richert Allen C AC, Kurnutala Lakshmi N LN

Electroconvulsive therapy (ECT) is usually performed under general anesthesia using a sedative-hypnotic and a short-acting neuromuscular blocker, typically without instrumentation of the airway. We report a case of pulmonary aspiration during ECT in a 27-year-old man on multiple psychotropic medications who was fully compliant with standard American Society of Anesthesiologists (ASA) preoperative fasting (Nil per Os, NPO) guidelines. A postprocedure point-of-care (POC) gastric ultrasound revealed a full stomach with solid contents. The cumulative anticholinergic burden of his medication regimen, including clozapine, benztropine, quetiapine, paliperidone, and prazosin, combined with the recognized association between psychiatric illness and disordered gastric motility, likely contributed to retained gastric contents at the time of induction. We review the limitations of fasting-based risk assessment, the prevalence of residual gastric content in appropriately fasted patients, the evidence supporting POC gastric ultrasound as a decision-support tool, and the practical constraints of equipment availability and operator training. We propose a risk-stratified approach in which preprocedural POC gastric ultrasound is recommended for ECT patients with one or more risk factors for delayed gastric emptying-rather than as a universal, mandatory examination.

PubMedThe world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry2026-07-13

Sexual function despite hyperprolactinemia: a 24-month analysis of paliperidone palmitate versus haloperidol decanoate.

Serretti Alessandro A

Sexual dysfunction is common in schizophrenia and may contribute to poor quality of life and non-adherence. Paliperidone palmitate (PP) and haloperidol decanoate (HD) differ substantially in prolactin liability, but their long-term effects on sexual function are unclear. We compared 24-month ASEX trajectories and prolactin-ASEX associations in the ACLAIMS trial. In participants with ≥1 ASEX assessment, ASEX total score (5-30) was modelled longitudinally with mixed-effects models for repeated measures (MMRM); the binary sexual-dysfunction outcome was modelled with generalised estimating equations (GEE). Prolactin was assessed from months -0.5-24, and prolactin-ASEX associations were examined by sex. 175 participants were included (PP n = 86; HD n = 89). Baseline dysfunction prevalence was 49% in both arms. PP produced higher prolactin throughout follow-up (all p<.001), but ASEX trajectories did not differ significantly. An exploratory month 22-24 window comparison favoured PP (p=.019). Greater prolactin rise from baseline was associated with overall ASEX worsening at month 12 (r = 0.21, p=.013), with concordant but non-significant sex-specific estimates (males r = 0.15; females r = 0.30). Despite higher prolactin with PP, ASEX trajectories were similar between PP and HD. A late PP-favouring signal was observed. Greater within-person prolactin increase was associated with later sexual-function worsening across the cohort.

+1788 more articles available with a free account

Sign up free to view all articles →

Ask about paliperidone